Research evidence / Overview of Studies for Tanvimil A
Evidence for Use in Systemic Deficiency and Prophylaxis
This section will summarize the body of research, including large-scale meta-analyses and randomized controlled trials, that investigated whether oral Vitamin A supplementation was associated with differences in mortality, morbidity, and blood status markers in populations with endemic deficiency.
The majority of research on this supplement has been studied for its role in preventing or correcting Systemic Vitamin A Deficiency (VAD). The research base includes extensive Systematic Reviews, Meta-analyses, and large Randomized Controlled Trials (RCTs), supplemented by observational studies. These major trials primarily examined children and infants (aged 6 months to 5 years) living in populations where VAD is a recognized public health issue. Researchers monitored vital outcomes such as all-cause mortality, rates of specific causes of death (like diarrhea), the incidence of common infections, and changes in the level of retinol in the blood (a key biomarker).
High-level evidence syntheses reported observations related to differences in all-cause mortality patterns between supplemented populations and control groups in high-burden settings. Research highlights changes measured during the study period showing an alteration in the retinol biomarker status following supplementation. Studies also examined the prevalence and reported severity of symptoms related to eye dryness (xerophthalmia) and night blindness in the observed populations. However, data show patterns related to the incidence of all infections were described as mixed and heterogeneous across different studies.
What remains uncertain is the generalizability of these observational patterns to populations who already have adequate Vitamin A status. The results apply only to the populations studied, which were heavily focused on VAD-endemic regions. Furthermore, existing studies provide limited insight into the influence of other co-occurring nutrient deficiencies (like zinc) on the observed outcomes. Long-term effects and the durability of response following the end of the typical dosing interval are not fully established in large-scale trials.
Evidence for Supportive Management during Acute Infection
This part will review the specific randomized clinical trials and systematic reviews that have examined the role of oral Vitamin A as a supportive measure during acute infectious diseases, such as measles, focusing on the study populations, measured outcomes, and the duration of observation.
The supplement was studied for use in conditions associated with acute or disruptive episodes, specifically measles. Research relies on RCTs and synthesis reports that inform official health agency recommendations. The studies evaluated the supplement in hospitalized children diagnosed with acute measles, with many trials focusing on the age group under two years. Researchers monitored mortality related to measles, the incidence of severe complications (like pneumonia), and the duration of clinical symptoms, such as fever and diarrhea.
Trials reported measurements related to potential differences in measles-related mortality in children under two years receiving the supplement during the acute phase of illness. Some trials described patterns where the duration of fever and diarrhea was observed to be different when compared to control groups. However, data are still emerging, and studies reported varying levels of consistency regarding the reduction of specific complications across different clinical settings.
The evidence is limited in terms of its application to children over 2 years of age in this specific context. Furthermore, research primarily focuses on the severely ill, hospitalized population, which means limited information is available for children with milder infections who are treated outside of a hospital setting. The precise role of high-dose supplementation in the acute phase of this illness, beyond simply restoring status, is not fully established in the current research.
Research on Status Improvement in High-Risk Nutritional Groups
Here we will outline the studies, including trials involving pregnant and lactating women, that tracked changes in maternal and breast milk Vitamin A status and assessed the findings related to specific outcomes like maternal night blindness and infant health markers.
Oral Vitamin A supplementation was evaluated in specific high-risk nutritional groups, notably pregnant and lactating women in areas where VAD is a public health issue. The research, comprising RCTs and Observational Studies, examined changes in retinol concentrations in maternal blood and breast milk. Studies also explored clinical outcomes such as maternal night blindness, and monitored various health endpoints in their offspring.
Some trials reported that supplementation was associated with an increase in serum and breast milk retinol concentrations, which research highlights a change in nutritional biomarker status. Studies also described patterns suggesting an association between supplementation and a change in the incidence of night blindness in mothers. However, findings regarding the effects of maternal supplementation on infant mortality or long-term morbidity were mixed and highly variable across trials.
Evidence quality varies across studies in this area due to high variability in trial design, the dose used, and the deficiency level of the populations studied. Therefore, subgroup findings are uncertain, and comparative evidence is lacking for the effects of supplementation on some long-term infant outcomes.
Long-Term Studies and Follow-up
This heading will summarize what is known and unknown about long-term outcomes, durability of response, and any extended-duration data.
While most of the key evidence was studied for short-term changes in status or episodic or acute changes in illness, some research has examined outcomes beyond the acute treatment phase. The follow-up durations in the major mortality trials extend over multiple years, providing some data for long-term patterns in death rates in supplemented children.
However, long-term effects are not fully established regarding the durability of retinol status or its influence on chronic conditions later in life. Most follow-up durations were primarily focused on the time necessary to assess the effect of the dosing cycle (typically 4 to 6 months) rather than tracking outcomes across a full lifetime. There is limited information for long-term outcomes regarding non-mortality endpoints, such as long-term functional status.
Evidence in Specific Populations
This section will describe what research exists for distinct populations, such as infants, young children, or those with underlying malabsorption conditions, noting which groups were included in major trials and the specific endpoints that were studied.
The core of the evidence was studied for infants and young children (6 months to 5 years), who are considered the primary target population for VAD control programs. Beyond this, research examined individuals with malabsorption disorders (e.g., cystic fibrosis, liver disease) as they are prone to deficiency due to systemic or functional imbalance. These studies monitored the effect of supplementation on serum retinol levels and general nutritional status markers in these groups.
As noted previously, data for certain groups remain insufficient. For instance, the evidence specific to older adults or those with multiple comorbid conditions not related to malabsorption is less well-characterized by large-scale randomized trials. The main findings regarding mortality differences results apply only to the populations studied (children in endemic areas) and cannot be assumed for all age groups or conditions.
What Research Indicates is Still Uncertain
This final section will synthesize the major knowledge gaps and areas of research uncertainty, including inconsistent findings across different studies, limitations regarding applicability to non-deficient populations, and areas where more research is needed.
The research landscape highlights what is known—and what is still uncertain. Major uncertainty surrounds the applicability of the results to individuals who are not deficient or who live in high-income settings where deficiency is rare; the observed patterns in high-burden settings research does not determine whether an individual will respond similarly in a low-burden setting.
Additionally, the research indicates that the findings varied regarding specific, non-fatal outcomes, such as rates of common infectious morbidities like respiratory infection. There are limited data for these specific morbidity outcomes due to heterogeneity and inconsistency among studies. Finally, comparative evidence is lacking for certain subgroups, and research is ongoing to better characterize the long-term functional effects of supplementation as studied in early life.
Key Studies & References
- WHO Guideline: Vitamin A supplementation in pregnant women
